September 16, 20240 citations

Supplementary Fig. 6 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)

LSLuna De Sutter AWAgnieszka Woźniak JVJasper Verreet

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Fig. 6. One histologically representative picture of cPARP staining in control group versus IDRX-42₂5 treatment group in the experiment with UZLX-GIST9KIT11+17.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Sutter et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523cc0 https://doi.org/10.1158/1078-0432.27031855.v1

Ask AI

Helpful

Bookmark

View Full Paper

September 16, 20240 citations

Supplementary Fig. 6 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)

View Full Paper

LSLuna De Sutter AWAgnieszka Woźniak JVJasper Verreet

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Fig. 6. One histologically representative picture of cPARP staining in control group versus IDRX-42₂5 treatment group in the experiment with UZLX-GIST9KIT11+17.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Sutter et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523cc0 https://doi.org/10.1158/1078-0432.27031855.v1

Ask AI

Helpful

Bookmark

View Full Paper